跳至主要内容
临床试验/NCT01942005
NCT01942005已完成不适用

EVER/TMC Mutation as Marker of the Risk of Cutaneous Carcinoma in Immunosuppressed Patients,Especially Patients After Organ Transplantation and Patients With HIV Infection

Andreas Arnold1 个研究点 分布在 1 个国家目标入组 144 人开始时间: 2010年1月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
144
试验地点
1
主要终点
Detection of mutation / specific polymorphism of the EVER/TMC6 and/or EVER/TMC8 gen.

研究概览

简要总结

Detection of mutation / specific polymorphism of the EVER/TMC6 and/or EVER/TMC8 gen.

详细描述

correlation between possibly detected mutation/specific polymorphism and kind and number of neoplasm, age of patients, UV burden, duration and kind of immunosuppression.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •patients in an immunosuppressive condition either by immunosuppressants or by HIV infection

排除标准

  • •written informed consent not given

结局指标

主要结局

Detection of mutation / specific polymorphism of the EVER/TMC6 and/or EVER/TMC8 gen.

时间窗: 7 years

次要结局

  • correlation between possibly detected mutation/specific polymorphism of the EVER/TMC6 and/or EVER/TMC8 gen and a composite of kind and number of neoplasm, age of patients, UV burden, duration and kind of immunosuppression.(7 years)

研究者

发起方
Andreas Arnold
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Andreas Arnold

Dr. med. Andreas Arnold, senior physician

University Hospital, Basel, Switzerland

研究点 (1)

Loading locations...

相似试验